



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)

C07K 16/30 (2006.01) C07K 16/46 (2006.01)

(21) International Application Number:

PCT/GB2018/053280

(22) International Filing Date:

13 November 2018 (13.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1718734.5 13 November 2017 (13.11.2017) GB

1718735.2 13 November 2017 (13.11.2017) GB

1808589.4 24 May 2018 (24.05.2018) GB

(71) Applicant: CRESCENDO BIOLOGICS LIMITED

[GB/GB]; Meditrina Building 260, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).

(72) Inventors: BRUCKLACHER, Verena; c/o Crescendo Bi-

ologics Limited, Meditrina Building 260, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). EDWARDS, Carolyn; c/o Crescendo Biologics Limited, Meditrina Building 260, Babraham Research Cam-

pus, Cambridge Cambridgeshire CB22 3AT (GB). LEGG, James; c/o Crescendo Biologics Limited, Meditrina Building 260, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). MAJITHIYA, Jayesh; c/o Crescendo Biologics Limited, Meditrina Building 260, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB). ROSSANT, Christine; c/o Crescendo Biologics Limited, Meditrina Building 260, Babraham Research Campus, Cambridge Cambridgeshire CB22 3AT (GB).

(74) Agent: APPLEYARD LEES IP LLP; 15 Clare Road, Halifax Yorkshire HX1 2HY (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: MOLECULES THAT BIND TO CD137 AND PSMA




FIG. 6

(57) Abstract: The disclosure relates to agents that simultaneously bind CD137 and PSMA and which comprise a single domain antibody specific to CD137 and a moiety that binds PSMA. The disclosure also relates to therapeutic and diagnostic applications of such agents, for example in the treatment or detection of a cancer.

[Continued on next page]



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))